Clinoptilolite for Treatment of Dyslipidemia: Preliminary Efficacy Study

Cutovic, Milisav; Lazović, Milica; Vukovic-Dejanovic, Vesna; Nikolić, Dejan; Petronić-Marković, Ivana; Ćirović, Dragana

doi:10.1089/acm.2016.0414

Cited by 12 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Similarly, it has been given orally to patients for the treatment of dyslipidemia with no effect on blood lipid levels nor other harmful consequences. 29 Clinoptilolite has been used to successfully control severe diarrheal diseases in cattle and pigs, 30 and its efficacy and tolerability led to the human anti-diarrheal drug Enterex, a drug developed in Cuba. Based on its immunomodulatory and biological ion-exchange capacities, the beneficial clinical properties of clinoptilolite have been accepted by the pharmaceutical communities in the European Union and the USA as safe for human use https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3039.…”

Section: Discussionmentioning

confidence: 99%

Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial

Pavelić

Micek

Bobinac

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

The severity of osteoporosis in humans manifests in its high incidence and by its complications that diminish quality of life. A societal consequence of osteoporosis is the substantial burden that it inflicts upon patients and their families. Several bone-modifying drugs have been prescribed to patients with osteoporosis. However, evidence for their anti-fracture efficacy remains inconclusive. To the contrary, long-term use of anti-osteoporotic drugs such as bisphosphonates and Denosumab, an RANKL inhibitor, have resulted in adverse events. We now present an alternative and adjuvant approach for treatment of osteoporosis. The data derive from in vivo studies in an ovariectomized rat model and from a randomized double blind, placebo-controlled human clinical study. Both studies involved treatment with Panaceo Micro Activation (PMA)-zeolite-clinoptilolite, a defined cation exchange clinoptilolite, which clearly improved all bone histomorphometric parameters examined from ovariectomized animals, indicative for increased bone formation. Moreover, intervention with PMA-zeolite-clinoptilolite for one year proved safe in humans. Furthermore, patients treated with PMA-zeolite-clinoptilolite showed an increase in bone mineral density, an elevated level of markers indicative of bone formation, a significant reduction in pain, and significantly improved quality of life compared with patients in the control (placebo) group. These encouraging positive effects of PMA-zeolite-clinoptilolite on bone integrity and on osteoporosis warrant further evaluation of treatment with PMA-zeolite-clinoptilolite as a new alternative adjuvant therapy for osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial

Pavelić

Micek

Bobinac

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…In case of antioxidant enzymes, these co-factors may include the coenzyme Q10, vitamins B1 and B2, carnitine, selenium, and often transition metals Cu, Mn, Fe, and Zn ( Khalid, 2007 ). Recently, a preliminary efficacy study performed on patients with dyslipidemia has also shown a positive effect of clinoptilolite supplementation on lowering the total lipid count and LDL (low density lipoproteins), which may also be indirectly correlated with its general antioxidative effect ( Cutovic et al, 2017 ).…”

Section: Zeolites Effects On Oxidative Stress and Immune Systemmentioning

confidence: 99%

Critical Review on Zeolite Clinoptilolite Safety and Medical Applications in vivo

et al. 2018

View full text Add to dashboard Cite

Unique and outstanding physical and chemical properties of zeolite materials make them extremely useful in a variety of applications including agronomy, ecology, manufacturing, and industrial processes. Recently, a more specific application of one naturally occurring zeolite material, clinoptilolite, has been widely studied in veterinary and human medicine. Due to a number of positive effects on health, including detoxification properties, the usage of clinoptilolite-based products in vivo has increased enormously. However, concerns have been raised in the public about the safety of clinoptilolite materials for in vivo applications. Here, we review the scientific literature on the health effects and safety in medical applications of different clinoptilolite-based materials and propose some comprehensive, scientifically-based hypotheses on possible biological mechanisms underlying the observed effects on the health and body homeostasis. We focus on the safety of the clinoptilolite material and the positive medical effects related to detoxification, immune response, and the general health status.

show abstract

“…Modulation of the ROS-regulated signaling pathways and oxidative damage to cells and tissues is related to the pathogenesis of a wide number of diseases, including atherosclerosis, hypertension, neurological diseases, and cancer [12]. In this regard, a preliminary efficacy study with patients suffering from dyslipidemia and orally supplementing a zeolite (clinoptilolite material) lowered the total lipid count and low-density lipoproteins (LDL)-this might also be indirectly correlated with the general antioxidative effect [27].…”

Section: Introductionmentioning

confidence: 99%

ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy

et al. 2020

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is the most frequently reported adverse effect of oxaliplatin. In this study, we set out to evaluate the role of the panaceo-micro-activation (PMA) zeolite in the reduction of the incidence of CIPN and hematological and liver toxicity. The possible impact of the PMA-zeolite as an adjuvant therapeutic agent is based on its detoxification properties toward agents promoting the development of neuropathy (e.g., ammonium – recognized as a neurotoxic agent produced by tumors), as well as its positive impact on immunity and oxidative stress through its effects in the gastrointestinal tract. From April 2015 to October 2018, a total of 120 patients (pts) diagnosed with predominantly colorectal cancer requiring oxaliplatin-based chemotherapy were randomized to receive either the PMA-zeolite (Multizeo Med) or placebo while undergoing oxaliplatin-based chemotherapy. A nerve-conduction study (NCS) was planned at the baseline, after three and six months of chemotherapy, to evaluate CIPN. Furthermore, the evaluation of hematological and liver toxicity was performed during every cycle of chemotherapy. 70.6% and 64.3% of patients developed CIPN in the placebo and the PMA-zeolite group, respectively. Patients treated with the PMA-zeolite were able to undergo more cycles of chemotherapy (p = 0.03), which also indicates a significant improvement in tolerance to the therapy. The group treated with the PMA-zeolite showed a lower CIPN (although not statistically significant within the whole group of subjects) compared to patients receiving placebo. This advantage was, however, statistically significant in men (p = 0.047). In addition, supplementation with the PMA-zeolite resulted in a lower incidence of severe-grade hematological toxicity (trend toward statistical significance of p = 0.09 was observed). Cancer patients may benefit from the therapy with the appropriate certified zeolite-products (e.g., the PMA-zeolite) for human use in CIPN. The lower CIPN (statistically significant results in the male subgroup) was accompanied by a trend of lower incidence of severe-grade hematological toxicity. Furthermore, these benefits led to a better tolerance toward chemotherapy (increase in cycles) and allow an improved compliance with the oncological treatment protocol.

show abstract

Clinoptilolite for Treatment of Dyslipidemia: Preliminary Efficacy Study

Abstract: These pilot results suggest that oral administration of clinoptilolite may improve lipid profile in individuals with dyslipidemia, which warrants further investigations.

Cited by 12 publications

References 33 publications

Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial

Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial

Critical Review on Zeolite Clinoptilolite Safety and Medical Applications in vivo

ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy

Contact Info

Product

Resources

About